---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-022825"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T02:28:23.912269+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics halts all programs, explores strategic alternatives

## Summary
- Halts all development programs; will explore strategic alternatives including acquisition, merger, or business combination.
- Received Nasdaq deficiency notice for common stock bid price below $1.00 for 30 consecutive trading days.
- Has 180 days (until July 31, 2023) to regain compliance with minimum bid price requirement.
- No timetable set for strategic review; no assurance a transaction will be completed.

## SEC filing metadata
- accession: 0001193125-23-022825
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/0001193125-23-022825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/d445995d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-022825
- JSON: https://secwatch.observer/filing/0001193125-23-022825.json
- Plain text: https://secwatch.observer/filing/0001193125-23-022825.txt

## Key facts
- Listing & Compliance Notices
  Dianthus Therapeutics, Inc. /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5810(c)(3)(A)
  source text: January 31, 2023, Magenta Therapeutics, Inc. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutive business day period between December 15, 2022 through January 30, 2023, the Company’s common stock, $0.001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/0001193125-23-022825-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.